Vichem’s most important strategic partner is a research institute of the Max Planck Society located in Martinsried, a suburb of Munich, whom we are developing several kinase inhibitors for numerous targets.
ViroStatics is committed to discover and develop innovative, first-in class, disease-modifying medicines that address the unmet medical needs in viral infections, cancers and inflammatory diseases and has developed a core platform of novel compounds from which to explore these multiple indications.
Oncotyrol is the Austrian center for translational research in personalized cancer medicine. Oncotyrol is based on the outstanding basic research and long-lasting experience in clinical oncology in Tyrol. From Tyrol it can reach out to connect scientific, clinical and industrial partners from all over the world.
Vichem collaborates with Oncotyrol in three significant projects: Multiple myeloma in the FP7 OPTATIO project, development of novel BRaf inhibitors and cancer stem cell project.
German biomedical basic research is widely considered to be world-class. However, there is vast room for improvement when it comes to transforming the basic findings into commercially viable and medically valuable products. It is a potential that the LDC is exploiting, transforming innovative research into pharmaceutical applications in close cooperation with academic partners. The LDC sees itself as a “translational drug discovery center” which paves the way for innovative drugs and therapies for the benefit of the patient.
Semmelweis University, university for medicine and health-related disciplines, located in Budapest, Hungary is named after the Hungarian physician Ignaz Semmelweis.
Semmelweis University has an over 230-year old tradition of academic excellence and commitment to the education of physicians. Among Semmelweis alumni there are Nobel-laureates, world renowned researchers and clinicians. Current enrolment at the Faculty of Medicine is 2907 students, at the Faculty of Dentistry 500, and at the Faculty of Pharmacy 604. Four percent of all medical students are foreign citizens studying in Hungarian.
A multidisciplinary approach is being used by UPCOL to tackle major public health problems such as tuberculosis (TB) and leprosy. The unit comprises experts in genomics, functional genomics, bioinformatics, biochemistry, chemistry and structural biology. Using genome biology as a platform we are actively involved in discovering new drugs to treat TB and believe that knowledge gained through discovery must be broadly and swiftly disseminated. Given the global importance of the TB problem, we are trying to strike the correct balance between competition and collaboration. In addition to numerous collaborations in the context of the EPFL and the framework of NM4TB, we are also collaborating with other leading European and American scientists such as Professor Pedro Alzari, Professor Patrick Brennan, Dr. Roland Brosch and Dr. Christophe Guilhot.
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities, located in Biopolis and Fusionopolis as well as their immediate vicinity.
A*STAR supports Singapore’s key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, hospitals, research centres, and with other local and international partners.
Proteros is Europe´s most experienced and largest biotechnology company in the field of X-ray protein structure analysis and a leading service partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies.
Focusing on services, Proteros provides protein crystallography, access to various complementary compound libraries in conjunction with unique assay technologies and medicinal chemistry capabilities to generate novel lead compounds for therapeutically relevant targets.
Proteros is privately owned and was co-founded by Nobel Prize winner Prof. Dr. Robert Huber, one of the pioneers of structural and functional analysis of proteins.